160 related articles for article (PubMed ID: 37773882)
1. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort.
Vicente-Valor J; García-González X; Ibáñez-García S; Durán-García ME; de Lorenzo-Pinto A; Rodríguez-González C; Méndez-Fernández I; Percovich-Hualpa JC; Herranz-Alonso A; Sanjurjo-Sáez M
Biomed Pharmacother; 2022 Feb; 146():112519. PubMed ID: 34968928
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Davis LE; Pogge EK
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
[TBL] [Abstract][Full Text] [Related]
5. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
[TBL] [Abstract][Full Text] [Related]
7. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
[No Abstract] [Full Text] [Related]
8. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.
Kim OM; Givens TK; Tang EG; Schimmer JJ; Ramsey T; Boyd K; Delate T
J Cardiovasc Pharmacol; 2023 May; 81(5):339-347. PubMed ID: 36795508
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
[TBL] [Abstract][Full Text] [Related]
10. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM
Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306
[TBL] [Abstract][Full Text] [Related]
11. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
12. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
14. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
Rehberger Likozar A; Ugovšek S; Šebeštjen M
Eur J Pharmacol; 2024 Jan; 963():176232. PubMed ID: 38070635
[TBL] [Abstract][Full Text] [Related]
15. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
16. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
17. Application of PCSK9 Inhibitors in Practice.
Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
[TBL] [Abstract][Full Text] [Related]
19. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
[TBL] [Abstract][Full Text] [Related]
20. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
